TTrialPathMatch Me to Trials
← Back to trials
RecruitingAtypical Teratoid/Rhabdoid TumorEmbryonal Tumor With Multilayered RosettesEwing Sarcoma

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Eligible age

Up to 26 yrs

Accepts

All genders

Locations

12 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat. The goals of this part of the study are: * Establish a recommended dose of AMXT 1501 in combination with DFMO * Test the safety and tolerability of AMXT 1501 in combination with DFMO * To determine the activity of study treatments chosen based on: * How each subject responds to the study treatment * How long a subject lives without their disease returning/progressing

Sponsor: Milton S. Hershey Medical Center

You may qualify if…

  • ✓ 1. Age:
  • ✓ All participants : Must be a maximum of 26 years of age at diagnosis
  • ✓ Age at enrollment by Phase:
  • ✓ 1. Safety Run-in (Dose level 1)-The first three (3) participants enrolled will be ≥ 12 years of age at enrollment. Once evaluated for safety by DSMB, we will move on to the next three (3) participants enrolled who will be ≥6 years of age at enrollment. Once evaluated for safety by DSMB, we will move on to the Phase I.
  • ✓ 2. Phase I and II: ≤ 26 years of age at diagnosis.
  • ✓ 2. Pathology
  • ✓ All participants must have a confirmed pathologic diagnosis of tumor type (except for DIPG):
  • ✓ Relapsed/refractory Neuroblastoma (NB)

You may not qualify if…

  • ✕ 1. BSA of \<0.25 m2
  • ✕ 2. Investigational Drugs: Participants who are currently receiving another investigational drug are excluded from participation.
  • ✕ 3. Anti-cancer Agents: Participants who are currently receiving other anticancer agents are not eligible. Participants must have fully recovered from the hematological and bone marrow suppression effects of prior chemotherapy.
  • ✕ 4. Infection: Participants who have an uncontrolled infection are not eligible until the infection is judged to be well controlled in the opinion of the investigator.
  • ✕ 5. Participants who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study, or in whom compliance is likely to be suboptimal, should be excluded.

Where it's recruiting

Alabama

Birmingham

Arkansas

Little Rock

Connecticut

Hartford

Florida

Gainesville · Miami · Orlando · Tampa

Hawaii

Honolulu

Kansas

Kansas City

Michigan

Grand Rapids

Missouri

St Louis

New Jersey

Hackensack

Tennessee

Nashville

Texas

Austin · Dallas

Source: ClinicalTrials.gov · NCT06465199 · last updated 2026-11-19

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and S · TrialPath